The risk of corruption in public pharmaceutical procurement: how anti-corruption, transparency and accountability measures may reduce this risk
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index; 3 of the 37 sources its claims cite were checked for support.
Abstract
Background: The goal of the public procurement of pharmaceuticals is to purchase sufficient quantities of high-quality pharmaceuticals at cost-effective prices for a given population. This goal can be undercut if corruption infiltrates the procurement process. Good procurement practices can help mitigate the risks of corruption and support equitable access to affordable and high-quality medicines.Objectives: This paper aims to 1) examine manifestations of corruption in the pharmaceutical procurement process and key factors behind them, and 2) identify how to design and implement effective anti-corruption, transparency and accountability mechanisms within this process.Methods: This paper was informed by a narrative literature review from 1996 to the present. The search focused on publications that addressed the issue of pharmaceutical procurement and governance and corruption issues. Our search included peer-reviewed literature, books, grey literature such as working papers, reports published by international organizations and donor agencies, and some media articles. Some documents used in this paper were already known to the authors.Results: Procurement is highly vulnerable to corruption particularly in the health sector. What is more, corruption in the procurement process does not appear to be limited to any one level of government or type of health system. The better integration of accountability, transparency and anti-corruption mechanisms in the procurement process is needed to reduce the risk of corruption.Conclusions: Lessons learned suggest that anti-corruption, transparency and accountability mechanisms in the pharmaceutical procurement process, such as open contracting and integrity pacts are helpful towards reducing the risk of corruption.
Overview
CoChat Summary
TL;DR
This narrative review argues that public pharmaceutical procurement is highly vulnerable to corruption and that stronger transparency, accountability, and anti-corruption (ACTA) measures can reduce that risk. It highlights examples such as open contracting, e-procurement, integrity pacts, and stronger audits/oversight as promising tools, but stresses that they are not sufficient on their own.
Key findings
- The review concludes that procurement is “highly vulnerable to corruption,” especially in health, and that corruption can occur at national, state/provincial, and local levels in both centralized and decentralized systems.
- Corruption can appear at every procurement stage: pre-bidding, bidding, and post-bidding; examples given include falsified needs, biased bids, bribery/extortion, false invoicing, and rewriting contract terms.
- The paper gives concrete examples of scale and impact: in a World Bank review of five health projects in India (FY 2007–2008), evidence of fraud and corruption was found in all five; in a Latin America hospital study, high-to-low purchase price ratios ranged from 3:1 to 35:1; in one country report, prices for essential medicines were up to 41% higher than international averages.
- The authors argue that transparency and accountability can help by exposing patterns/outliers, enabling price comparison, supporting sanctions, and improving monitoring; they cite open contracting and e-procurement as useful, but “necessary but insufficient” without additional governance measures.
Methods
- Narrative literature review covering publications from 1996 to the present.
- Search strategy used PubMed, PAIS, and Summon with corruption/procurement/pharmaceutical/governance keywords; included peer-reviewed articles, books, grey literature, reports, and some media articles.
- Search yielded 2,038 results, reduced to 99 articles, and then to a final pool of 62 cited articles; the search was limited to English-language sources.
Limitations
- The paper states that the search was limited to English sources and that the cited articles are “not exhaustive.”
- It also notes that “some documents used in this paper were already known to the authors,” which makes the review partly reliant on prior familiarity rather than a fully systematic search.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
2 Valid · 2 Not valid · 31 Not checked · 20 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Procurement is highly vulnerable to corruption particularly in the health sector.”
- Also stated in: § Background · boosted
“public procurement holds the greatest risk for corruption amongst all government functions [3].”
- Also stated in: § Background · boosted
“Despite global anti-corruption efforts to date, public procurement contracts remain highly vulnerable to corruption [11].”
§ The risk of corruption in public pharmaceutical procurement: how anti-corruption, transparency and accountability measures may reduce this risk > Abstract
What the sources say
- Not matchedcites [3]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Partly supportedcites [11] sourceExperimental — accuracy not yet measured
The “Challenges faced” section says many public procurement activities suffer from differing levels of corruption, and the “Payment” section describes a potential for manipulation in hospital drug procurement. The paper does not establish that procurement is especially vulnerable in the health sector compared with other sectors. (LLM, conf=0.84)
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Background · boosted
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Conflict-of-interest declarations can also be used to monitor relationships between physicians and the pharmaceutical industry and to avoid pre-bidding corruption, so long as there are adequate follow-up measures to address conflict of interest once it is revealed [22].”
§ The risk of corruption in public pharmaceutical procurement: how anti-corruption, transparency and accountability measures may reduce this risk > Results > Examples of ACTA mechanisms in procurement
What the sources say
- Partly supportedcites [22] sourceExperimental — accuracy not yet measured
The Background (page unavailable) discusses physician-directed pharmaceutical marketing transparency laws, while the Discussion, ‘Assessment of pharmaceutical governance initiatives’ (page unavailable), discusses evaluating conflict-of-interest policies. The paper also describes electronic bidding as a way to curb procurement corruption, but our copy does not say that conflict-of-interest declarations monitor physician–industry relationships or prevent pre-bidding corruption when followed up. (LLM, conf=0.75)
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
In the paper
“corruption in the procurement process does not appear to be limited to any one level of government or type of health system.”
- Also stated in: § Background · plain
“Corruption is not limited to a particular type of health system structure. It is present in systems that are public or private, well or poorly funded, and technically simple or complex [10].”
- Also stated in: § Where corruption in public procurement occurs · plain
“Corruption in procurement is not limited to one location or type of procurement system. It can occur at the national, state/provincial, or local levels, and is found in centralized and decentralized procurement systems alike.”
§ The risk of corruption in public pharmaceutical procurement: how anti-corruption, transparency and accountability measures may reduce this risk > Abstract
What the sources say
- Not matchedcites [10]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Background · plain
In the paper
“The World Bank’s Review included a broad-based forensic review of procurement practices in five World Bank health projects in the country. The review discovered evidence of fraud and corruption in all of the projects, undercutting their goals [29].”
§ The risk of corruption in public pharmaceutical procurement: how anti-corruption, transparency and accountability measures may reduce this risk > Results > Examples
What the sources say
- Not matchedcites [29]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Our review illuminates how corruption in procurement often occurs when there are insufficient ACTA measures embedded throughout the procurement process from pre-bidding to delivery of goods.”
§ The risk of corruption in public pharmaceutical procurement: how anti-corruption, transparency and accountability measures may reduce this risk > Conclusion This article highlights findings from our narrative literature review that focused on corruption risks in the public procurement of pharmaceuticals and ACTA measures to address it. The intent of this article was to strategically illuminate key issues and to provide examples related to the topic. Corruption significantly undercuts public health goals, including ensuring access to essential medicine, which is a sub-target of Sustainable Development Goal # 3. Our review illuminates how corruption in procurement often occurs when there are insufficient ACTA measures embedded throughout the procurement process from pre-bidding to delivery of goods. Evidence suggests that procurement can be strengthened through the integration of ACTA in its processes. This may include first undertaking corruption risk assessments in the pharmaceutical procurement area and based on findings from the assessments implement appropriate ACTA measures. Equally important, risk management strategies to address corruption, which is discussed by others in this volume, are helpful to apply in the procurement of medicines, in order to ensure that if there are potential vulnerabilities to corruption, they are identified and appropriately addressed. Still, knowing what is needed to be put in place to ensure the sustainability of ACTA measures procurement, does demand further research and capacity building, and could potentially be an area of focus for the WHO, the UNDP and the Global Fund under the ACTA for Health Alliance.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
19 more claims
Create a free account to see all 55 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 27
- Probably not a substantial claim. 13
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Existing literature recognises the positive and significant role of transparency in reducing corruption in public health service delivery (Yang, 2018;Kohler and Dimancesco, 2020;Lega and Castellini, 2022).”
From Promoting transparency and accountability towards anti-corruption in pharmaceutical procurement system: does e-procurement play a significant role? (2024) · cites this paper as Kohler and Dimancesco, 2020
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Consistent with existing literature (Kohler and Dimancesco, 2020;Koller et al., 2020;Mackey and Cuomo, 2020), the findings of this study recognise accountability as a fundamental and critical element in enhancing efforts to combat procurement corruption.”
From Promoting transparency and accountability towards anti-corruption in pharmaceutical procurement system: does e-procurement play a significant role? (2024) · cites this paper as Kohler and Dimancesco, 2020
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“While AI offers significant benefits, it also poses ethical challenges that public administration must address.”
From Balancing efficiency and ethics in public administration: The role of artificial intelligence in administrative law of the Middle East (2025) · cites this paper as Kohler and Dimancesco, 2020
Experimental — accuracy not yet measured
Citations
Cites
Klitgaard, R. (2019) · doi:10.1525/9780520911185 · Cited by 1,423
The Self-Restraining State: Power and Accountability in New Democracies
(1999) · Lynne Rienner Publishers eBooks · doi:10.1515/9781685854133 · Cited by 723
Accountability and health systems: toward conceptual clarity and policy relevance
Brinkerhoff, D. W. (2004) · Health Policy and Planning · doi:10.1093/heapol/czh052 · Cited by 458 · cited 1×
“mechanisms that make institutions responsive to the publics they serve [41,44,46].”
BackgroundReview of corruption in the health sector: theory, methods and interventions
Vian, T. (2007) · Health Policy and Planning · doi:10.1093/heapol/czm048 · Cited by 422 · cited 2×
“case corrupt behaviour is detected [55].”
The Accountability Cube: Measuring Accountability
Brandsma, G. J., & Schillemans, T. (2013) · Journal of Public Administration Research and Theory · doi:10.1093/jopart/mus034 · Cited by 278
Seidman, G., & Atun, R. (2017) · BMJ Global Health · doi:10.1136/bmjgh-2016-000243 · Cited by 133 · cited 2×
“The health system as a whole may become less effective and equitable [14].”
BackgroundBaldi, S., & Vannoni, D. (2015) · Regional Studies · doi:10.1080/00343404.2015.1101517 · Cited by 92
Diagnosis Corruption: Fraud in Latin America's Public Hospitals
Tella, R. D., & Savedoff, W. D. (2001) · Cited by 85
Increasing transparency and accountability in national pharmaceutical systems
Paschke, A., Dimancesco, D., Vian, T., Kohler, J. C., & Forte, G. (2018) · Bulletin of the World Health Organization · doi:10.2471/blt.17.206516 · Cited by 63
Self-citationSchmitz, H. P. (2013) · Global Public Health · doi:10.1080/17441692.2013.830143 · Cited by 58
Research works printed but not linked: 12
- Strombom D., 1998, Econ Perspect, 3, 1
- Savedoff WD, Hussmann K Why are health systems prone to corruption? Transparency International, Global Corruption Report 2006. London, UK: Pluto Press; 2006.
- Transparency International G20 Position Paper, 2016, Transparency in Health Sector Procurement
- World Bank, 2007, Corruption and technology in public procurement
- World Health Organization, 2009, Measuring transparency in the public pharmaceutical sector: assessment instrument
- Vian T, 2016, Medicines Transparency Alliance (MeTA): pathways to transparency, accountability and access
- Vian T, 2010, Anti-corruption in the health sector: strategies for transparency and accountability
- Organisation for Economic Co-operation and Development Health and Public Procurement, 2009, OECD
- The Law of Ukraine. About Public Procurement, 2015, Document 922-VIII, current edition
- Cohen JC, 2001, Using technology to fight corruption in pharmaceutical purchasing: lessons learned from the chilean experience
- Navarrete E, 2014, CUENTA PÚBLICA 2013 [Public account 2013] Central de Abastecimiento S.N.S.S. Ministerio de Salud
- Engstrom A, 2009, Proc Int Multiconference Comput Sci Inf Technol, 4, 315
Cited by
Malik, M. A. (2022) · Global Health Journal · doi:10.1016/j.glohj.2022.01.006 · Cited by 98
Köhler, J. C., & Bowra, A. (2020) · Globalization and Health · doi:10.1186/s12992-020-00629-5 · Cited by 101
Self-citationKöhler, J. C., & Wright, T. (2020) · Journal of Pharmaceutical Policy and Practice · doi:10.1186/s40545-020-00256-w · Cited by 71
“Yet, when corruption infiltrates the pharmaceutical procurement processes, health goals can be threatened by possible consequences such as pharmaceutical shortages, inflated drug prices, and the distribution of falsified and substandard essential medicines [7].”
BackgroundInfluentialSelf-citationSaeed, G., Kohler, J. C., Cuomo, R. E., & Mackey, T. K. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2091543 · Cited by 33
“whether a supplier is reliable) [26], increasing their chances of selecting the best supplier.”
BackgroundInfluentialThe Global Fund: why anti-corruption, transparency and accountability matter
Chang, Z., Rusu, V., & Köhler, J. C. (2021) · Globalization and Health · doi:10.1186/s12992-021-00753-w · Cited by 34
“Corruption has a global reach; it can manifest in many forms across various types of institutions, fuelling inequity and working to undermine global health efforts such as universal health coverage and other health targets designated in the UN’s Sustainable Development Goals (SDGs) [8, 11].”
BackgroundInfluentialSelf-citation
Metadata
- Authors
- Kohler, J. C., & Dimancesco, D.
- Affiliations
- Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada
- World Health Organization (CH)
- ORCID
- Dimancesco, Deirdre
- Venue
- Global Health Action
- Publisher
- Informa UK Limited
- Published
- 2020-02-03
- Volume
- 13
- Issue
- sup1
- Pages
- 1694745
- ISSN
- 1654-9716 (ISSN-L)
- 1654-9880
- PMC
- PMC7170361
- OpenAlex
- W3011937804
- Cited by
- 128
- References
- 21
- Citations by year
- 2026: 14 · 2025: 21 · 2024: 24 · 2023: 33 · 2022: 20 · 2021: 10 · 2020: 6
- FWCI
- 2.65
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Global Health Action (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- World Health Organization
- Topics
- Social Sciences › Business, Management and Accounting › Strategy and Management › Public Procurement and Policy
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Social Sciences › Sociology and Political Science › Corruption and Economic Development
- Keywords
- corruption, anti-corruption mechanisms, transparency, accountability, integrity pact, health system governance, equitable access to medicines, procurement risk
- MeSH terms
- Pharmaceutical Preparations, Fraud, Government Programs, Humans, Social Responsibility
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The risk of corruption in public pharmaceutical procurement: how anti-corruption, transparency and accountability measures may reduce this risk. https://app.cochat.ai/papers/10.1080/16549716.2019.1694745
- The paper
- Kohler, J. C., & Dimancesco, D. (2020). The risk of corruption in public pharmaceutical procurement: how anti-corruption, transparency and accountability measures may reduce this risk. Global Health Action. https://doi.org/10.1080/16549716.2019.1694745
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.